DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Erygel is a drug marketed by Mylan and is included in one NDA.
The generic ingredient in ERYGEL is erythromycin. There are one hundred and three drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
A generic version of ERYGEL was approved as erythromycin by TORRENT on July 6th, 2020.
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Mylan||ERYGEL||erythromycin||GEL;TOPICAL||050617-001||Oct 21, 1987||AT||RX||Yes||Yes||Start Trial||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|